Germany’s Health‑Spending Cuts Prompt Lilly and Boehringer to Scale Back German Investments

Germany's newly proposed health‑spending cutbacks and stricter drug‑pricing rules are causing major pharmaceutical companies to scale back investments in the country.

Eli Lilly will halve its planned €2.3 billion investment in a new factory in Alzey, Rhineland‑Palatinate, now expecting to spend about €1 billion and create roughly 500 jobs instead of 1,000, citing the government's planned health‑reform framework as a key reason.

Boehringer Ingelheim is cutting more than €900 million in planned domestic investments from 2027 to 2030, explicitly linking the decision to the federal government's savings plans and higher drug discounts required from pharmaceutical firms.

Industry leaders warn that the legislation, championed by Federal Health Minister Nina Warken, undermines investment predictability and sends a "terrible signal" to the pharmaceutical sector, potentially weakening Germany's position as a leading European pharma hub.